Clinical trial
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial
NCT04620200 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Patients Prior to Standard of Care Surgery; the MATISSE Trial
- Lead sponsor
- The Netherlands Cancer Institute
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 11, 2020
- Completion date
- January 7, 2025
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.